114 hospitalized patients suffering from endogenous depression were treated with Ludiomil. The average daily dose was 125 mg (range: 50-300 mg), administered orally and/or by the parenteral route. The therapeutic efficacy, assessed by means of a modified Hamilton Rating Scale, was already evident after the first week of treatment. After the third week of treatment, 38% of the cases showed complete recovery, 45% showed a marked reduction of the depressive symptoms, and only 17% showed only slight improvement or none at all. In view of the good efficacy obtained and also considering the low dosage used and the absence of unwanted effects, it is concluded that Ludiomil is to be recommended in the treatment of dysthymic depression.
|Translated title of the contribution||Clinical trial of maprotiline in endogenous depression|
|Number of pages||10|
|Journal||Rassegna di Studi Psichiatrici|
|Publication status||Published - 1980|
ASJC Scopus subject areas
- Psychiatry and Mental health